Mouse anti-Human p170-Glycoprotein (MDR) (unconjugated), Clone JSB-1, IgG1, Ready-to-use

Ready-to-use Antibody for Immunohistochemistry

5 ml


The antibody JSB-1 reacts with a cytoplasmic epitope of a plasma membrane associated glycose protein (170 -180 kD). It is also referred to as P-170 glycose protein due to its molecular weight (“P” for permeability). The P-glycose protein points to a strong structural similarity with the transport proteins of bacteria.
P-glycose proteins are found in various normal cells and are capable of transporting toxic substances out of cells. These cells typically have secretory or excretory properties, such as the renal proximal tubules, bile ducts, and adrenal cortex.

Reagents sufficient for about 50-100 tissue sections

  • 1 dropper bottle HISTOPRIME® P170 Glycoprotein (MDR) (Bottle, 5 ml


P-Glycoprotein (170kD)


Recognition of a cytoplasmic epitope of plasma membrane associated P-Glycoprotein.


HAT-29 colon carcinoma cell line

Normal Tissue

High expression in liver, kidney, colon, adrenal gland, pancreas and lung
Low expression in bone marrow, ovary, muscle, prostate, stomach, brain




Mouse lgG1

Fusion Partners

BALB/c mice were immunized with the multidrug-resistant cell line CHrC5 derived from Chinese hamster ovarian tissue. After fusion of spleen cells from these mice with SP2/0 myeloma cells, the antibody-producing clone was identified by immunocytochemical staining of MDR cell lines.

Increased expression of P-glycose protein is preferentially found in tumors derived from tissues in which it is originally present. These are mainly liver carcinomas, kidney carcinomas, colorectal carcinomas and carcinomas of the adrenal glands. In most untreated tumors from other tissues, P-glycose protein can only be detected in small amounts.
That phenomenon of multidrug resistance of tumor cells describes the simultaneous presence of cellular resistance to various cytostatics, antibiotics, alkaloids, or anthracyclines. This resistance is thought to be caused by increased expression of the P-glycose protein.
The detection of a multidrug-resistant phenotype may have important consequences for therapy. First, it can be determined if tumors are resistant before therapy is started, and second, it can be determined during treatment when resistance occurs. In both cases, other drugs can be used for therapy.


After formaldehyde fixation and kerosene embedding, unmasking with HISTOSAFE-ENHANCER (LINARIS CatNr E7000) for 10-20 min at 96°C in a water bath or 2 x 5 min microwave 600 Watt is recommended. Also possible is pretreatment with 0.1% Pronase (LINARIS CatNr E110) 10 min room temperature.

Incubation Period

1 hour at room temperature


Ready-to-use in PBS, BSA, NaN3 (0,09%) pH 7,4(*) suitable on cryostat sections and on formalin-fixed, paraffin-embedded tissue sections.

Control Tissue

Liver, Kidney, Colon, Adrenal, Pancreas, Lung

Recommended Secondary Reagents

Alkaline Phosphatase Vectastain® ABC Mouse IgG (Vector CatNo AK-5002) and Substrate-Kit e.g. Vector® Red (Vector CatNo SK-5100)
Peroxidase Vectastain® ABC-Elite Mouse IgG (Vector CatNo PK-6102) and Peroxidase Substrate-Kit e.g. DAB (LINARIS CatNo E108) or HistoGreen (LINARIS CatNo E109 ).

  • Bell D.R., Gerlach J.H., Buick R.N., Ling V. (1985) Detection of P-Glycoprotein in ovarian cancer. Molecular marker associated with
    multidrug resistance. J. Clin. Oncol.3; 311-315
  • Gerrlach J.H., Bell D.R., Karakousis C., Slocum H.K., Kartner N., Rustum Y.M., Ling V., Baker M. (1987), 1452
  • Ma D.D.F., davey R.A., Harmann D.H., Isbister J.P., ScurrR.D., Mackertich S.M. Dowden G., Bell D.R. (1987) Detection of a multidrug
    resistant phenotype in acute nonlymphblastic leukaemia. Lancet 1; 135.
  • Scheper, R.J. et al. (1988) Int. J. Cancer 42; 389-394

p170-Glycoprotein (MDR)

Species Reactivity


Host / Source









Human p170-Glycoprotein (MDR)


5 ml



Storage Temperature

2-8 °C

Shipping Temperature

20 °C


pdf Datasheet